226 related articles for article (PubMed ID: 21306583)
21. Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor.
January B; Seibold A; Allal C; Whaley BS; Knoll BJ; Moore RH; Dickey BF; Barber R; Clark RB
Br J Pharmacol; 1998 Feb; 123(4):701-11. PubMed ID: 9517390
[TBL] [Abstract][Full Text] [Related]
22. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
23. β2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids.
Holden NS; Bell MJ; Rider CF; King EM; Gaunt DD; Leigh R; Johnson M; Siderovski DP; Heximer SP; Giembycz MA; Newton R
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19713-8. PubMed ID: 22080612
[TBL] [Abstract][Full Text] [Related]
24. Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro.
Anderson P; Lötvall J; Lindén A
Lung; 1996; 174(3):159-70. PubMed ID: 8830192
[TBL] [Abstract][Full Text] [Related]
25. Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha).
Finney PA; Donnelly LE; Belvisi MG; Chuang TT; Birrell M; Harris A; Mak JC; Scorer C; Barnes PJ; Adcock IM; Giembycz MA
Br J Pharmacol; 2001 Mar; 132(6):1261-70. PubMed ID: 11250877
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
[TBL] [Abstract][Full Text] [Related]
27. Clinical pharmacology of long-acting beta-receptor agonists.
Tattersfield AE
Life Sci; 1993; 52(26):2161-9. PubMed ID: 8099697
[TBL] [Abstract][Full Text] [Related]
28. Duration of action of inhaled vs. Intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model.
Mohammed SP; Taylor CV; Weyman-Jones CB; Mather ME; Vendy K; Dougall IG; Young A
Pulm Pharmacol Ther; 2000; 13(6):287-92. PubMed ID: 11061983
[TBL] [Abstract][Full Text] [Related]
29. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
Politiek MJ; Boorsma M; Aalbers R
Eur Respir J; 1999 May; 13(5):988-92. PubMed ID: 10414394
[TBL] [Abstract][Full Text] [Related]
30. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor.
Patel S; Summerhill S; Stanley M; Perros-Huguet C; Trevethick MA
Pulm Pharmacol Ther; 2011 Apr; 24(2):247-55. PubMed ID: 21134482
[TBL] [Abstract][Full Text] [Related]
31. Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages.
Donnelly LE; Tudhope SJ; Fenwick PS; Barnes PJ
Eur Respir J; 2010 Jul; 36(1):178-86. PubMed ID: 19926732
[TBL] [Abstract][Full Text] [Related]
32. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi.
Molimard M; Naline E; Zhang Y; Le Gros V; Begaud B; Advenier C
Eur Respir J; 1998 Mar; 11(3):583-8. PubMed ID: 9596106
[TBL] [Abstract][Full Text] [Related]
33. Long-acting beta 2 agonists suppress IP-10 expression in human bronchial epithelial cells.
Chien JW; Chu YT; Yang SN; Kuo CH; Wang WL; Kuo PL; Jong YJ; Hung CH
J Investig Med; 2012 Oct; 60(7):1048-53. PubMed ID: 22914602
[TBL] [Abstract][Full Text] [Related]
34. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.
Bisgaard H
Pediatr Pulmonol; 2000 Mar; 29(3):221-34. PubMed ID: 10686044
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological similarities and differences between beta2-agonists.
Lötvall J
Respir Med; 2001 Aug; 95 Suppl B():S7-11. PubMed ID: 11534896
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.
Nicholls DJ; Jordan S; Cadogan E; Lawson M; Austin RP; Paine SW; Gardiner P; Bonnert R; Connolly S; Young A
Pulm Pharmacol Ther; 2012 Aug; 25(4):293-302. PubMed ID: 22659538
[TBL] [Abstract][Full Text] [Related]
37. Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells.
Chu YT; Chang TT; Jong YJ; Kuo PL; Lee HM; Lee MS; Chang HW; Hung CH
Pediatr Allergy Immunol; 2010 Mar; 21(2 Pt 1):345-52. PubMed ID: 20003162
[TBL] [Abstract][Full Text] [Related]
38. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
Ryall JG; Sillence MN; Lynch GS
Br J Pharmacol; 2006 Mar; 147(6):587-95. PubMed ID: 16432501
[TBL] [Abstract][Full Text] [Related]
39. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
Kuna P
Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
[TBL] [Abstract][Full Text] [Related]
40. The effects of beta 2-adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes.
Linden M
Br J Pharmacol; 1992 Sep; 107(1):156-60. PubMed ID: 1358381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
